Xiangmin Cui - 28 Sep 2021 Form 4 Insider Report for Cue Health Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 28 Sep 2021
Net transaction value: +$10,092,045
SEC form: 4
Accepted by SEC: 30 Sep 2021, 17:43:03 UTC
Prior SEC filing: 23 Sep 2021
Next SEC filing: 04 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Erica Palsis, Attorney-in-Fact for Xiangmin Cui

Key filing fact

Xiangmin Cui filed Form 4 for Cue Health Inc. on 30 Sep 2021.

Key facts

This page summarizes Xiangmin Cui's Form 4 filing for Cue Health Inc..
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Sep 2021, 17:43.

Change

Previous filing in this sequence was filed on 23 Sep 2021.
Current net transaction value: +$10,092,045.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HLTH transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +8,192,468
Change %
Price
Shares after: 8,192,468
Date: 28 Sep 2021
Ownership: See Footnote
Footnotes: F1, F2

HLTH transaction

Common Stock

Award

Transaction value: $10,092,045
Shares: +788,441
Change %
Price: $12.80^*
Shares after: 788,441
Date: 28 Sep 2021
Ownership: See Footnote
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HLTH transaction Derivative

Series C-1 Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -8,192,468
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 8,192,468
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Footnote F2

The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. The reporting person is the manager of the GP and disclaims beneficial ownership of such securities held by the Fund, except to the extent of his pecuniary interest therein, if any.

Footnote F3

On September 28, 2021, outstanding principal and accrued interest underlying a convertible note automatically converted into Common Stock upon the closing of the initial public offering of the Issuer's common stock at a conversion price equal to 80% of the initial public offering price per share.

Footnote F4

The shares are held directly by Decheng Capital Global Healthcare Fund (Master), LLC, whose general partner is Decheng Capital Global Healthcare GP, LLC. The reporting person is the sole member and manager of Decheng Capital Global Healthcare GP, LLC. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.